LuxCreo, Inc. appears in FDA premarket notification records as the applicant for dental devices spanning software and resin materials. The most recent entry in the supplied collection is LuxDesign, a Class II orthodontic software device under product code PNN and regulation 872.5470, recorded with a substantially equivalent decision dated October 23, 2026, following a submission received February 9, 2026. Earlier FDA records name LuxCreo as submitter of a clear aligner system and a flexible partial denture resin. The company’s own published pages describe a dental ecosystem of printers, software and materials, with LuxDesign presented as software for direct-printed aligners, retainers and night guards. [1][2][3][8][9]
LuxDesign and the software record
FDA record K260421 lists LuxCreo, Inc. as applicant for LuxDesign, described in the openFDA fields as orthodontic software, Class II, product code PNN, regulation number 872.5470, with the dental advisory committee. The decision code is SESE, described as substantially equivalent, with a decision date of October 23, 2026 and a Traditional clearance type; the record notes a statement rather than a summary. The filing address on the record is in Chicago, Illinois, and the listed contact is Feng Tao. [1][2]
LuxCreo’s own product page presents LuxDesign as software for direct-print dental appliances, naming aligners, retainers and EMA 3D among its uses, and describes dual modes including a Fast Track AI Mode. The same page states that appliances can be generated in minutes and references LuxCreo’s ISO-certified quality. A separate software page states that an aligner, retainer or night guard can be created in LuxDesign in less than four minutes. These are manufacturer claims about the product, not independently verified performance figures. [3][7]
Materials and aligner filings
An FDA clearance letter dated April 8, 2025 addresses K250343 for the LuxCreo Clear Aligner System, regulation 21 CFR 872.5470, Class II, product code NXC, with the submission dated and received March 10, 2025. The letter is addressed to Tao Feng, VP of Legal, at the Chicago address, and the accompanying submission lists LuxCreo Inc. as submitter with a registration and FEI number. [8]
A second clearance letter dated November 25, 2025 addresses K253365 for the LuxCreo Flexible Partial Denture Resin, regulation 21 CFR 872.3760, Class II, product code EBI, dated September 29, 2025 and received September 30, 2025. A document within that filing describes the resin as engineered for 3D printing of digitally designed flexible partial denture bases and references LuxCreo’s Digital Polishing platform. The company’s site lists flexible partial denture among its dental applications. [4][9]
The described dental workflow
LuxCreo’s published materials describe an ecosystem organized around hardware, software and materials. The hardware pages name the iLux Pro Dental printer, iLuxWash Dental and iLuxCure Pro Dental post-processing units; the software pages name LuxFlow Pro, LuxDesign and LuxLink; and the materials pages reference LuxCreo Materials, Partner Materials and ActiveMemory Polymer. A digital platform, LuxCloud Dental, and services including 4D Express, installation and training, and maintenance and support are also listed. [3][4][5]
The company’s about page describes a platform for personalized medical and dental devices and states a mission of supporting same-day treatment through onsite production and laboratory design and production services, citing FDA-cleared direct-print technology, AI-empowered software and materials. A software overview page describes LuxFlow and LuxDesign as tools for operating LuxCreo’s 3D printers at single-printer or production scale. These descriptions originate with the manufacturer. [5][7]
What the filing record shows
The supplied collection, as of November 20, 2026, contains one linked 510(k) record, K260421, with a single SESE decision; the record sample is that same single entry, so the collection and sample counts coincide at this snapshot. The collection is not a measure of total company sales, total portfolio or safety performance. The additional FDA letters for K250343 and K253365 appear in the numbered sources but are not part of the linked collection counts. [1][8][9]
Across the records, LuxCreo, Inc. is identified as the applicant or submitter, with Tao Feng listed as contact or VP of Legal. The sources do not establish a parent company, brand ownership, headquarters or customer base, and the Chicago address appears as a filing address rather than a stated headquarters. No recall records appear in the supplied sample. [1][8][9]

